MDGL Madrigal Pharmaceuticals
- 229.840
- +13.790+6.38%
Madrigal Pharmaceuticals News
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Madrigal Statement on the Passing of Dr. Stephen Harrison
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison.We offer our deepest condolences to Stephen's family f
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results And Host Webcast on May 7, 2024
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2
United Healthcare's Favorable Insurance Coverage of Rezdiffra Boosts Madrigal Pharmaceuticals Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardinal Health (CAH) and Madrigal Pharmaceuticals (MDGL)
Express News | Madrigal Pharmaceuticals Shares Down 5.7% After BofA Initiates Coverage With Underperform Rating
BofA Skipping Celebration of Madrigal's Rezdiffra -- Market Talk
1121 ET - Madrigal Pharmaceuticals has won many fans on Wall Street since scoring the first FDA approval of a drug to treat the fatty liver disease known as MASH, but Bank of America isn't among them.
Express News | Madrigal Pharmaceuticals Inc : BofA Global Research Initiates Coverage With Underperform Rating; Price Objective $150
Madrigal Pharmaceuticals Initiated at Underperform by B of A Securities
Madrigal Pharmaceuticals Initiated at Underperform by B of A Securities
Express News | B of A Securities Initiates Coverage On Madrigal Pharmaceuticals With Underperform Rating, Announces Price Target of $150
Madrigal Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 -29.58% B of A Securities → $150 Initiates Coverage On → Underperform 03/20/2024 90.14% Evercor
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Latest Insider Selling in April 2024: 10 Stocks to Watch
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing
Paul A Friedman, Director, on April 08, 2024, sold 26,270 shares in Madrigal Pharmaceuticals (MDGL) for $6,467,491. Following the Form 4 filing with the SEC, Friedman has control over a total of 841,2
Madrigal Pharmaceuticals(MDGL.US) Officer Sells US$658.26K in Common Stock
$Madrigal Pharmaceuticals(MDGL.US)$ Officer Taub Rebecca sold 2,676 shares of common stock on Apr 8, 2024 at an average price of $245.9857 for a total value of $658.26K.Source: Announcement What is st
Madrigal Pharmaceuticals(MDGL.US) Director Sells US$6.47 Million in Common Stock
$Madrigal Pharmaceuticals(MDGL.US)$ Director FRIEDMAN PAUL A sold 26,270 shares of common stock on Apr 8, 2024 at an average price of $246.193 for a total value of $6.47 million.Source: Announcement W
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals Says Rezdiffra Available in US
Madrigal Pharmaceuticals (MDGL) said Tuesday that its Rezdiffra liver disease treatment is now available in the US. Rezdiffra is indicated, with diet and exercise, for the treatment of adults with non
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (Resmetirom) for the Treatment of Patients With Noncirrhotic NASH With Moderate to Advanced Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Rezdiffra (resmetirom) is now available in the U.S. Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Analysis
Price Target
No Data
